CN1 over-expression aggravates disease progression and mitigates the beneficial effect of carnosine in type 2 diabetic mice
Jian-ggo Qiu(Heidelberg University), Sibylle J. Hauske(Heidelberg University), B Yard(Heidelberg University), Diego O. Pastene(Heidelberg University), SHUYAO ZHANG(Heidelberg University), Thomas Albrecht(Heidelberg University), A Rodriguez(Heidelberg University)
Cited by 0
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
|Circulation|2020|282
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
|Clinical Kidney Journal|2018|239
Carnosine Attenuates the Development of both Type 2 Diabetes and Diabetic Nephropathy in BTBR ob/ob Mice
|Scientific Reports|2017|127
International consensus definitions of clinical trial outcomes for kidney failure: 2020
|Kidney International|2020|121